The 10-second takeaway
For the quarter ended June 30 (Q2), Vascular Solutions beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share grew.
Gross margins improved, operating margins increased, net margins dropped.
Vascular Solutions booked revenue of $24.7 million. The five analysts polled by S&P Capital IQ anticipated revenue of $24.2 million on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $22.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.15. The three earnings estimates compiled by S&P Capital IQ forecast $0.13 per share. GAAP EPS of $0.15 for Q2 were 15% higher than the prior-year quarter's $0.13 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 66.7%, 70 basis points better than the prior-year quarter. Operating margin was 15.9%, 70 basis points better than the prior-year quarter. Net margin was 9.6%, 10 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $24.2 million. On the bottom line, the average EPS estimate is $0.14.
Next year's average estimate for revenue is $97.7 million. The average EPS estimate is $0.55.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 95 members out of 107 rating the stock outperform, and 12 members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 20 give Vascular Solutions a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vascular Solutions is buy, with an average price target of $14.30.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Vascular Solutions the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add Vascular Solutions to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is the co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.